Tsumura’s April–September net profit rises 30% to ¥16.2 billion
Tsumura announced consolidated net profit of ¥16.2 billion for April–September 2026, up 30% from a year earlier. Sales of Kampo medicines increased in Japan, while making Yomeishu Seizo a subsidiary also contributed. Revenue rose 15% to ¥103.4 billion, and operating profit increased 10% to ¥18.8 billion.